Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB-267268 inhibits human and mouse αvβ3 (IC50s: 0.68 and 0.29 nM, respectively). SB-267268 is a selective and nonpeptidic alpha(v)beta3 and alpha(v)beta5 integrins antagonist (Kis: 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | SB-267268 inhibits human and mouse αvβ3 (IC50s: 0.68 and 0.29 nM, respectively). SB-267268 is a selective and nonpeptidic alpha(v)beta3 and alpha(v)beta5 integrins antagonist (Kis: 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively). |
In vitro | SB-267268 inhibits the attachment of bothαvβ3-transfected HEK293 cells to microtiter plate wells precoated with arginine-glycine-aspartic acid (RGD)-containing matrix proteins (IC50: 12 nM). SB-267268 also inhibits vitronectin-mediated human and rat aortic smooth-muscle-cell (SMC) migration (IC50: approximately 12.3 nM and 3.6 nM, respectively) [1]. |
In vivo | SB-267268 (60 mg/kg; bi-daily, i.p.) decreases blood vessel profiles (BVPs) in the inner retina by 50%. VEGF and VEGFR-2 gene expression in the inner nuclear layer (INL) and the ganglion cell layer (GCL) is reduced in ROP mice treated with SB-267268 [1]. |
Molecular Weight | 451.44 |
Formula | C22H24F3N3O4 |
CAS No. | 205678-26-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB-267268 205678-26-8 Others SB 267268 SB267268 inhibitor inhibit